Analysis of major and minor IAS-USA PI mutations in the MONET trial of darunavir/ritonavir monotherapy versus DRV/r + 2NRTIs
نویسندگان
چکیده
Methods In the MONET trial, 256 patients with no history of virological failure and HIV RNA <50 copies/mL on current HAART (NNRTI based (43%), or PI based (57%) switched to either DRV/r monotherapy (800/100 mg OD) versus DRV/r + 2NRTIs. HIV RNA levels were evaluated at Weeks 2, 12, 24, 36, 48, 60, 72, 84 and 96: all patient samples with HIV RNA above 50 copies/mL were sent for genotypic resistance analysis (VircoTYPE HIV-1, Beerse, Belgium). Virtual phenotype was also assessed when PI mutations were detected. The percentage of patients with major or minor IAS-USA PI mutations was analysed by treatment arm.
منابع مشابه
Analysis of drug resistance during HIV RNA viraemia in the MONET trial of darunavir/ritonavir monotherapy.
BACKGROUND When patients have HIV RNA suppressed to <50 copies/ml on current treatment, switching to darunavir (DRV)/ritonavir (DRV/r) monotherapy could prevent the development of resistance to other drug classes. METHODS In the MONET trial, 256 patients with HIV RNA<50 copies/ml on current highly active antiretroviral therapy (57% with protease inhibitors [PIs] and 43% with non-nucleoside re...
متن کاملThe PROTEA trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV-1 RNA below 50 copies/mL
INTRODUCTION In previous studies, protease inhibitor (PI) monotherapy has shown trends for higher low-level elevations in HIV-1 RNA compared to triple therapy, but no increase in the risk of drug resistance. METHODS A total of 273 patients with HIV-1 RNA <50 copies/mL for over 24 weeks on current antiretrovirals switched to DRV/r (darunavir/ritonavir) 800/100 mg once-daily, either as monother...
متن کاملLow-level viraemia during treatment with darunavir/r monotherapy versus DRV/r + 2NRTIs in the MONET trial
Methods In the MONET trial, 256 patients with HIV RNA <50 copies/mL on current HAART, and no history of virological failure, switched to DRV/r 800/100 mg once daily, either as monotherapy (n=127) or with 2NRTI (n=129). HIV RNA was evaluated by the Roche Amplicor Ultrasensitive assay (lower detection limit=50 copies/mL), for all patient visits to Week 96. With this assay, “Optical Density=backgr...
متن کاملResistance mutations in protease gene at baseline are not related to virological failure in patients treated with darunavir/ritonavir monotherapy
INTRODUCTION Monotherapy with darunavir plus ritonavir (DRV/r) is a good maintenance strategy for suppressed HIV-infected patients. The clinical trials designed to prove the efficacy of PI/r do not include patients with resistance mutation in protease gene [1,2]. Sometimes in routine practice, basically to avoid NRTIs toxicity, monotherapy with DRV/r is used despite PI resistance mutations. The...
متن کاملAnalysis of neurocognitive function and CNS endpoints in the PROTEA trial: darunavir/ritonavir with or without nucleoside analogues
INTRODUCTION During treatment with protease inhibitor monotherapy, the number of antiretrovirals with therapeutic concentrations in the cerebrospinal fluid (CSF) is lower, compared to standard triple therapy. However, the clinical consequences are unclear. METHODS A total of 273 patients with HIV RNA <50 copies/mL for over 24 weeks on current antiretrovirals randomized to darunavir/ritonavir ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره 13 شماره
صفحات -
تاریخ انتشار 2010